51P - Active immunotherapy with a VEGF targeted vaccine HeberSaVax: the road so far and the future ahead

Date 05 March 2018
Event TAT 2018 - Targeted Anticancer Therapies
Session Selected poster presentations
Topics Immunotherapy
Presenter Mónica Bequet-Romero
Citation Annals of Oncology (2018) 29 (suppl_3): iii10-iii34. 10.1093/annonc/mdy047
Authors M. Bequet-Romero1, Y.M. Díaz1, J.S. Ramírez1, K. Selman-Housein2, F. Hernández-Bernal3, A. De la Torre Santos4, J. Piñero4, C. Bermúdez3, J.V. Gavilondo Cowley1, M. Ayala Avila1
  • 1Pharmaceuticals, Center for Genetic Engeneering and Biotechnology, 10600 - Cubanacán, Playa/CU
  • 2General Medicine, Center of Medical and Surgical Research, 10600 - Havana/CU
  • 3Clinical Research, Center for Genetic Engeneering and Biotechnology, 10600 - Cubanacán, Playa/CU
  • 4Oncology, Celestino Hernández Robau Hospital, 000 - Santa Clara/CU


The vascular endothelial growth factor (VEGF) plays a central role in angiogenesis and immunosuppressive cascades inherent to tumor development. Success of drugs targeting this growth factor and their receptors signaling cascade built upon these facts. Such passive targeting of VEGF/VEGFR pathway had two major caveats: non-manageable side effects and the induction of resistance phenomena. To overcome some of these problems we design an active immunization approach based on the use of a functionally deficient VEGF 121 isoform as antigen. Herein we present preclinical and clinical development data of HeberSaVax vaccine (formerly known as CIGB-247).